18 Jul Kenai Therapeutics
Nick Manusos, CEO
Oct. 7 | 2:00pm | FLW Ballroom G
San Diego, CA
(Private)
Kenai Therapeutics is a very soon to be clinical stage, neurodegenertive disease focused, biotechnology company utilizing an iPSC platform to replace the lost neurons in the central brain caused by Parkinson’s Disease (RNDP-001). RNDP-001 is an allogeniec, cryopreserved alternative. Leveraging best in class pre clinical data and partnerships with leaders in the field such as FujiFilm Cellular Dynamics (iPSC’s) and ClearPoint Neuro (surgical device), Kenai successfully completed an $82mm series A financing in February of 2024. Use of proceeds for the series A are focused on Kenai’s phase I trial which is set to initiate prior to the Mesa Meeting. Kenai’s pipeliine further expands on the lead program (RNDP-001) and addresses additonal unmet needs across the Parkinson’s disease patient spectrum such as cognition and inflammation. Also, Kenai is part of the Lilly Gateway Lab’s ecosystem and is based in San Diego.
